Skip to main content

Table 3 Plasma biomarker changes from baseline (week 0) to week 16. Data presented as Mean (SD)

From: A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Biomarkers Adjusted Means (SE)a
Placebo (n = 8) Riociguat (n = 9) p-value
cGMP (nM) 41.22 (50.2) 198.5 (47.03) 0.046
CXCL4 (ng/ml) -7.3 (105.9) -190.7 (99.8) 0.23
sE-Selectin (ng/ml) -2.5 (2.0) -4.7 (1.9) 0.45
VEGF (pg/ml) -34.7 (10.1) -29.8 (9.5) 0.73
sFLT1 (pg/ml) -218.0 (211.8) -220.5 (183.2) 0.99
tPA (ng/ml) -0.5 (0.5) -1.2 (0.5) 0.32
bFGF (pg/ml) -0.03 (0.29) 0.20 (0.28) 0.58
sICAM1 (ng/ml) -39.2 (50.2) 70.5 (47.3) 0.14
VCAM1 (ng/ml) -3.4 (11.0) 10.3 (10.4) 0.39
PINP (pg/ml) -6.6 (11.0) 7.1 (10.3) 0.38
MMP12 (ng/ml) 0.12 (0.14) -0.09 (0.13) 0.31
Endostatin (ng/ml) -96.8 (132.2) -299.0 (124.5) 0.29
  1. 1biomarker values analyzed on natural scale using ANCOVA, adjusting for baseline biomarker value